生物種
|
リソース名
|
RRC ID
|
タイトル
|
ジャーナル
|
公開日
|
外部リンク
|
ヒト・動物細胞
|
II-18(RCB2093)
|
77039
|
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
|
Br J Cancer |
2021-3-1 |
Pubmed
Full text
|
ヒト・動物細胞
|
CW-2(RCB0778)
,
MKN-7(RCB3687)
|
65780
|
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action.
|
Nat Commun |
2021-6-18 |
Pubmed
Full text
|
ヒト・動物細胞
|
HuCCT1(RCB1960)
,
TFK-1(RCB2537)
|
64967
|
Therapeutic implication of HER2 in advanced biliary tract cancer.
|
Oncotarget |
2016-9-6 |
Pubmed
Full text
|
ヒト・動物細胞
|
MCF7(RCB1904)
,
A549(RCB0098)
|
61366
|
Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
|
Eur J Med Chem |
2019-11-15 |
Pubmed
Full text
|
ヒト・動物細胞
|
CW-2(RCB0778)
|
58088
|
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
|
Cancer Cell |
2019-10-14 |
Pubmed
Full text
|
ヒト・動物細胞
|
ECC10(RCB0983)
,
GCIY(RCB0555)
,
MKN7(RCB0999)
|
56161
|
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
|
Cancer Sci |
2018-4-1 |
Pubmed
Full text
|
ヒト・動物細胞
|
Ba/F3(RCB0805)
|
55943
|
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
|
Lung Cancer |
2018-12-1 |
Pubmed
Full text
|
ヒト・動物細胞
|
HeLa(RCB0007)
|
54019
|
Construction of Anti-HER2 Recombinants as Targeting Modules for a Drug-delivery System Against HER2-positive Cells.
|
Anticancer Res |
2018-7-1 |
Pubmed
Full text
|
ヒト・動物細胞
|
CW-2(RCB0778)
|
51842
|
Overcoming resistance to HER2 inhibitors through state-specific kinase binding.
|
Nat Chem Biol |
2016-11-1 |
Pubmed
Full text
|
ヒト・動物細胞
|
MRC-5
|
42671
|
Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
|
Int J Urol |
2006-5-1 |
Pubmed
Full text
|
ヒト・動物細胞
|
TGBC1TKB(RCB1129)
|
38244
|
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
|
BMC Cancer |
2010-11-18 |
Pubmed
Full text
|